Document is current

Article History

Received: 2 January 2025

Accepted: 17 February 2025

First Online: 25 February 2025

Declarations

:

: Clinical studies were conducted in accordance with the Rules of Good Clinical Practice and the revised Declaration of Helsinki for Biomedical Research with Human Subjects. All subjects had no prior history of hypersensitivity or related reactions to steroid drugs and were physically normal. To confirm their physical health, all subjects underwent a physical examination, clinical screening, complete blood count, urinalysis, and blood chemistry analyses prior to participating in this clinical study.

: All subjects provided written informed consent prior to their participation in bioequivalence and pharmacokinetic studies.

: All data were anonymized, and participants were informed that the results of this study may be subject to publication and presentation in meetings.

: The authors declare no competing interests.

: The clinical trial protocols were thoroughly reviewed and officially approved by the Ministry of Food and Drug Safety (Cheongju-si, Republic of Korea). The approval number of the trial for levocetirizine was MB22-013. The approval number of the trial for rabeprazole was MB22-002.